Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer
Anti-Cancer Drugs, 07/02/09
Post S et al. - In a study to assess whether expression of topoisomerase I (Topo I) and thymidylate synthase (TS) helps predict treatment response in pts undergoing irinotecan and capecitabine-based chemoradiation, it was reported that Topo I expression in rectal tumour mucosa might serve as a predictor of response to neoadjuvant irinotecan-based chemoradiation, and might be a factor contributing to development of individualized treatment.
Methods- Pts with rectal cancer (cT3/4Nx or Tx/N+) received neoadjuvant chemoradiotherapy within clinical studies with irinotecan and capecitabine.
- Samples of normal and tumour tissues were collected before start of treatment and during surgical resection.
- Topo I and TS were measured using real-time PCR.
- 38 pts were analysed, 18 of them were responders.
- Biopsies of untreated tumour tissue of responding pts showed a significant higher expression of Topo I vs nonresponding pts.
- Normal tissue did not show this difference.
- During chemoradiation, Topo I expression in tumour tissue of responders decreased significantly.
- TS did not show any differences between responders and nonresponders before treatment, but a significant decrease in the tumour tissue of responders was noted at the end of treatment.
Related Articles
Obesity linked to specific cancers
Internet Source, 11/05/09
Relevance Score: 69%%
Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women
Cancer Causes and Control, 10/28/09
Relevance Score: 69%%
Childhood Cancer Survivors Experience Suicidal Thoughts Decades After Diagnosis
ScienceDaily, 10/27/09
Relevance Score: 69%%
American Cancer Society Stands by Cancer Screening Guidelines
MedLinePlus, 10/23/09
Relevance Score: 69%%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 69%%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Oncogene, 11/25/09
Embryoid body formation of human amniotic fluid stem cells depends on mTOR
Oncogene, 11/25/09
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A blood-based biomarker panel for stratifying current risk for colorectal cancer
International Journal of Cancer, 11/25/09
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Molecular Cancer, 11/24/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/29/09
A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma
Journal of Cancer Research & Clinical Oncology, 11/24/09
Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway
Journal of Clinical Oncology, 11/24/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/29/09
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


